Incomplete Freund's adjuvant
- Generic Name
- Incomplete Freund's adjuvant
- Drug Type
- Biotech
- Unique Ingredient Identifier
- Y9DQK7DB5U
KLH Challenge to Explore the Human Immune Response
- Conditions
- Immune Response
- Interventions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 39
- Registration Number
- NCT05876195
- Locations
- 🇬🇧
NIHR Oxford Experimental Medicine Clinical Research Facility, Oxford, United Kingdom
Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 15
- Registration Number
- NCT04842513
- Locations
- 🇩🇪
University Hospital Tübingen, Tübingen, BW, Germany
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
- Conditions
- Recurrent Glioblastoma
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- David Peereboom
- Target Recruit Count
- 41
- Registration Number
- NCT04013672
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
- Conditions
- Lung Atypical Carcinoid TumorMetastatic Pancreatic Neuroendocrine TumorLung Typical Carcinoid Tumor
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT03879694
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
- Conditions
- GlioblastomaGliosarcoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 66
- Registration Number
- NCT02455557
- Locations
- 🇺🇸
Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
- Conditions
- Partial Response of Multiple Myeloma or Plasma Cell LeukemiaPlasma Cell Myeloma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT02334865
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- Biological: WT1 126-134 peptide vaccineBiological: basiliximabOther: laboratory biomarker analysis
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 7
- Registration Number
- NCT01842139
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
- Conditions
- Recurrent MelanomaStage IIA MelanomaStage IIB MelanomaStage IIC MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma
- Interventions
- Biological: MART-1 antigenOther: laboratory biomarker analysis
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT01748747
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
- Conditions
- Melanoma (Skin)
- Interventions
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2023-01-18
- Target Recruit Count
- 127
- Registration Number
- NCT01176461
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
- Conditions
- Skin CancerMelanoma
- Interventions
- Procedure: RadiationGenetic: Anti-MART-1 F5 TCR PBL
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT00923195
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.